The US Supreme Court yesterday agreed to weigh in on a lower court ruling that weakened the Food and Drug Administration's 2016 and 2021 decisions to make the abortion medication mifepristone widely available.
Mifepristone, which has been around for more than two decades, is one of two drugs used for medically induced abortions. The pill is authorized for use up to 10 weeks into gestation and has been used by more than 5 million people since 2000 when the FDA approved the medication. See an overview of mifepristone here.
The high court will review an August ruling from a federal appeals court that upheld a lower court's restrictions to mifepristone, which include removing access to the medication by mail and shortening the timeframe for when the pill can be consumed from 10 weeks to seven weeks. The federal appeals court found the FDA didn't follow procedures when loosening regulations.
The Supreme Court is expected to take up the case in the spring, with a decision likely in late June.